Crossmark

Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting

Crossref DOI link: https://doi.org/10.1186/s12885-021-08291-9

Published Online: 2021-05-25

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Qianqian

Gao, Wen

Gao, Fangyan

Jin, Shidai

Qu, Tianyu

Lin, Fan

Zhang, Chen

Zhang, Jingya

Zhang, Zhihong

Chen, Liang

Guo, Renhua http://orcid.org/0000-0002-8589-5055
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (NSFC 81972188)

the Medical Important Talents (ZDRCA2016024)
License Information

Text and Data Mining valid from 2021-05-25

Version of Record valid from 2021-05-25
More Information

Article History

Received: 25 October 2020

Accepted: 4 May 2021

First Online: 25 May 2021

Declarations

:

: The study was approved by the First Affiliated Hospital of Nanjing Medical University Ethics Committee and complied with the ethical standards of the Declaration of Helsinki. All participants gave their written informed consent at registry inclusion.

: Not applicable.

: The authors declare that they have no conflict of interest.

Document is current

Any future updates will be listed below